Molecular biology was a hot new topic back in its infancy in the late 1980’s just as I was finishing my doctorate – cue moment of realising you’ve missed a big wave before it really even started!
Springtime in DC
These days scientists now delve in the realm of deeper molecular biology and go much further than mere genes… it’s all about transcription factors, super enhancers, chromatin complexes, bromodomains, and even chromodomains. In the past, many of these drivers were often considered ‘undruggable’ – think MYC or RAS, for example.
The world of molecular biology is rapidly changing as researchers understand pathways and processes associated with carcinogenesis better, thereby enabling new approaches to evolve and with it, valid new targets for therapeutic intervention.
This field is always one of my favourite ones to cover at AACR, where we not only learn about exciting new research from investigators, but also up and coming young biotech companies that are doing good work who deserve to be highlighted.
Subscribers can log in or you can sign up via the blue button below to learn more…
The White House in spring, Washington DC
With spring in the air and the clock rapidly running down on the annual meeting of the American Association for Cancer Research (AACR) in Washington DC in just two weeks time, it’s time to take a look at the seventh topic in our Preview series.
What’s hot on deck to day?
With increasing competition in the metastatic breast cancer space, particularly in HR+ HER2- disease, it’s time to explore key issues around CDK4/6 inhibitors as there’s a lot going on here, including some important presentations ahead.
A road map of what to expect and what to watch out for is often valuable if you want to avoid surprises.
We also examine key issues the companies here are facing as well as highlighting emerging scientific and clinical data of note on several relevant fronts.
To learn more, subscribers can log in below or you can sign up via the blue box below…
The recent PARP inhibitor data has stirred up a lot of interest amongst BSB subscribers (See post: PARP! PARP! what’s hot in ovarian cancer at SGO and AACR?).
So, rather than do another AACR 2017 Preview (more coming next week!), it seemed timely to take a look at some of the interesting questions we’ve received from subscribers.
Five questions have been selected for answer in this week’s BSB reader Q&A. We don’t award prizes if your question is selected, nor do we name who asked the question, but everyone benefits when interesting questions are asked and we can all learn from each other.
As author Thomas Berger aptly said:
“The art and science of asking questions is the source of all knowledge.”
What differentiates many world class cancer researchers is frequently the scientific questions they ask in their work. The same holds true if you are a C level executive or a journalist. The quality of the answer you obtain is often dependent on the quality of the question you ask.
We hope that being better informed about the issues and topics we write about on BSB will enable subscribers to ask better questions, and in the process make better decisions.
Subscribers can login to read more (and see if your question was answered) or you can gain access via the blue box below…
In the sixth Preview relating to the annual meeting at #AACR17, we take a closer look at an immuno-oncology topic that we are likely to see and hear more about over the next couple of years.
Indeed, I’ve followed some cancer conferences where it wasn’t even mentioned, much to my surprise. It should be, it’s likely going to be both needed and receive a lot of attention over the next few years.
What we need is a bridge for greater success. What does that look like though and how do we go about achieving it?
Subscribers can log-in to learn more or you can sign up via the blue box below…
There’s no secret or surprise with our latest AACR Preview as this week the focus takes a slight turns or detour to the annual meeting of the Society for Gynecology Oncology being held in National Harbor, Maryland.
PARP inhibitors in ovarian cancer have been a hot topic since last autumn when the PARP inhibitor data dropped at ESMO in Copenhagen, and was not without controversy either.
We’ve been following the trials, tribulations and even machinations, of the clinical development of olaparib, rucaparib and niraparib for a while now so what’s in store in the latest round of salvoes?
And importantly, what else can we expect to see in DC at AACR next month?
For a tumour type that hasn’t received much attention over the last decade or two, things are distinctly picking up. Is it all good though?
To learn more, subscribers can sign in below or you can sign up via the blue box to learn more about our insights…
MLK Memorial, Washington DC
We’re continuing our previews of the forthcoming 2017 annual meeting of the American Association for Cancer Research (AACR) in Washington DC with a look at an emerging pathway that may impact checkpoint therapy.
It’s an exciting time in cancer immunotherapy, although only a small minority of people have remarkable long-term durable responses and the reality is that most patients, even if they respond initially, end up relapsing at some point.
There’s still a lot to learn about cancer immunotherapy – we’re just scratching the surface of what’s possible.
At AACR17 we can expect to see insights on the direction the field is going. In this post we take a look at an emerging pathway, and some of the key presentations and posters that you should see if you are in DC for the meeting.
Subscribers can login to read more or you can gain access below…
After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in our third preview today we turn to look at a novel target.
This particular target hasn’t received much attention at all but this could well change in the future as some of the compounds move into the clinic.
There are a few important questions to consider:
- Who’s going to be first to evaluate in humans?
- Which tumour types will be optimal?
- Which combinations are likely to be synergistic, tolerable and effective?
- What path to market strategies will avoid the enrollment problems now that checkpoint blockade is becoming much more ubiquitous?
This is an interesting niche that may well evolve into a competitive landscape going forward.
Subscribers can log-in below or you can sign up via the blue box to learn more about our insights…
Today for the second AACR 2017 Preview, I wanted to switch things up a bit and turn from looking at an important trend to a specific tumour type. One of the reasons for this is that we received questions from readers about recent data presented at medical meetings in this sphere.
It’s also not something that we have covered extensively here on BSB, so looking at something in a different light is often a good idea since insights and intelligence can sometimes jump out afresh.
Given that there are also some important clinical trial results emerging here, this is something we can expect to return to in Washington DC when the data is presented at AACR next month. What can we learn ahead of the event though? It turns out the answer is quite a lot.
Subscribers can log-in below or you can sign-up via the blue button to learn more about our latest insights and analysis…
In the first of our 2017 AACR annual meeting previews, we are taking a look at a particular theme that we expect to hear much more about over the coming months.
Washington DC cherry blossoms
In order to make something better than what it is, we first need to step back and understand the various factors that underpin it. To do otherwise is akin to the proverbial throwing of mud at the wall and hoping something sticks.
Trying things out just because they seem like a good idea or that’s all you have in your pipeline doesn’t really inspire the greatest of confidence in a clinical trial’s success.
This is also where several factors including tumour biology, cancer genomics, biomarkers, and acquired resistance can intersect to produce some intriguing results.
Please note that our Conference Preview series are never random. When looking at the abstracts as a whole, we try to organise them around a particular scientific theme or a tumour type. The idea here is that it makes it much easier for our readers to see and grasp emerging concepts and trends. It’s also a deeper dive into the whys; things happen for a reason – why is that? What can we learn from the process?
These are also not random selections from say, publicly traded or private companies, big or small caps.
It does take more time to roll thematic articles out, but the advantage is that over the course of the next two weeks readers will be better equipped to get a grip on the meeting ahead of the event.
Indeed, a couple of subscribers even told us last year they learned more from our in-depth previews than they did from the meeting itself because it’s easy to miss the important things or become ‘bigly overwhelmed’ as one bio fund manager explained to me.
Strategically, we’ve taken one specific theme today and explored what we can expect based on what we have learned to date, and looked at how that will potentially impact a few things going forward.
Subscribers can log-in below or you can access our insights via the blue button…
Orlando, Florida: It’s time for a review of emerging science and clinical concepts. This post is the final one in our latest series from ASCO-SITC.
Here we take a step back and highlight six key emerging trends and ideas that were either presented in talks and posters, or are sentiments based on conversations with attendees in the poster halls or corridors.
Sometimes those discussions are pretty helpful in giving hints on new dirrections before the actual data eventually comes out.
Subscribers can log-in to read our insights or you can sign up via the blue box below…